BEAM
Price
$24.50
Change
+$0.11 (+0.45%)
Updated
Oct 2 closing price
Capitalization
2.5B
38 days until earnings call
Intraday BUY SELL Signals
IFRX
Price
$1.72
Change
+$0.01 (+0.58%)
Updated
Oct 2 closing price
Capitalization
268.21M
34 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs IFRX

BEAM vs IFRX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BEAM vs. IFRX commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and IFRX is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
BEAM vs IFRX: Fundamental Ratings
BEAM
IFRX
OUTLOOK RATING
1..100
965
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
85
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9297
PRICE GROWTH RATING
1..100
6447
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BEAM's Valuation (26) in the null industry is somewhat better than the same rating for IFRX (85) in the Biotechnology industry. This means that BEAM’s stock grew somewhat faster than IFRX’s over the last 12 months.

BEAM's Profit vs Risk Rating (100) in the null industry is in the same range as IFRX (100) in the Biotechnology industry. This means that BEAM’s stock grew similarly to IFRX’s over the last 12 months.

BEAM's SMR Rating (92) in the null industry is in the same range as IFRX (97) in the Biotechnology industry. This means that BEAM’s stock grew similarly to IFRX’s over the last 12 months.

IFRX's Price Growth Rating (47) in the Biotechnology industry is in the same range as BEAM (64) in the null industry. This means that IFRX’s stock grew similarly to BEAM’s over the last 12 months.

IFRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as BEAM (100) in the null industry. This means that IFRX’s stock grew similarly to BEAM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BEAMIFRX
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 1 day ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 11 days ago
77%
Bullish Trend 12 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 1 day ago
89%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (BEAM: $24.50 vs. IFRX: $1.72)
Brand notoriety: BEAM and IFRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 84% vs. IFRX: 62%
Market capitalization -- BEAM: $2.5B vs. IFRX: $268.21M
BEAM [@Biotechnology] is valued at $2.5B. IFRX’s [@Biotechnology] market capitalization is $268.21M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green while IFRX’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • IFRX’s FA Score: 0 green, 5 red.
According to our system of comparison, BEAM is a better buy in the long-term than IFRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 5 TA indicator(s) are bullish while IFRX’s TA Score has 4 bullish TA indicator(s).

  • BEAM’s TA Score: 5 bullish, 6 bearish.
  • IFRX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than IFRX.

Price Growth

BEAM (@Biotechnology) experienced а +0.95% price change this week, while IFRX (@Biotechnology) price change was -8.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.69%. For the same industry, the average monthly price growth was -14.41%, and the average quarterly price growth was -1.73%.

Reported Earning Dates

BEAM is expected to report earnings on Nov 09, 2026.

IFRX is expected to report earnings on Nov 06, 2026.

Industries' Descriptions

@Biotechnology (-3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
BEAM
Daily Signal:
Gain/Loss:
IFRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CRWU36.410.95
+2.68%
T-REX 2X Long CRWV Daily Target ETF
KIQQ25.180.04
+0.16%
KraneShares InspereX Nasdaq Dynamic Buffered High Income Index ETF (KIQQ)
HAWX45.32-0.08
-0.18%
iShares Currency Hedged MSCI ACWI ex U.S. ETF (HAWX)
IEV70.06-1.07
-1.50%
iShares Europe ETF (IEV)
GNOM68.78-1.70
-2.41%
Global X Genomics & Biotechnology ETF (GNOM)

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-0.25%
CRSP - BEAM
76%
Closely correlated
+0.22%
EDIT - BEAM
66%
Closely correlated
-1.95%
PRME - BEAM
66%
Loosely correlated
-2.13%
NTLA - BEAM
60%
Loosely correlated
+0.50%
RXRX - BEAM
60%
Loosely correlated
-1.45%
More